IRVINE, Calif. -- (Business Wire)
Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has
been filed against Avalanche Biotechnologies, Inc. (“Avalanche” or the
“Company”) (NASDAQ: AAVL).
Investors who purchased or otherwise acquired shares between July 31,
2014 and June 15, 2015, inclusive (the “Class Period”) are encouraged to
contact the Firm immediately to discuss their legal options.
If you purchased shares of Avalanche during the Class Period, please
contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman
Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by
email at joon@khanglaw.com.
There has been no class certification in this case. Until certification
occurs, you are not represented by an attorney. You may choose to take
no action and remain a passive class member.
According to the complaint, the Company allegedly issued materially
false and misleading statements and/or failed to disclose that Phase 2a
of the study for its drug AVA-101 was not designed to show any
statistical significance between the active and control groups in the
secondary endpoints.
If you purchased shares of Avalanche during the Class Period you have
until September 8, 2015 to ask the Court to appoint you as lead
plaintiff. If you wish to learn more about this lawsuit, or if you have
any questions concerning this notice or your rights, please contact Joon
M. Khang, a prominent litigator for almost two decades, by telephone:
(949) 419-3834, or by email at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150903006639/en/
Contacts:
KHANG & KHANG LLP
Joon M. Khang, Esq.
Telephone:
949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com
Source: Khang & Khang LLP
© 2024 Canjex Publishing Ltd. All rights reserved.